You are here: Industry Insights > Market News > WHO cautions against to ‘vaccine nationalism’

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

3-Bromo-4-fluorobenzaldehyde

5-Methyl-1,3,4-oxadiazol2(3H)-one

4-Amino-6-methyl-3 oxo2,3, 4,5-tetrahydro 1.2.4-triazine hydrochloride

4-Acetylamino-6-methyl -3-oxo-2,3,4,5-tetrahydro-1,2,4-triazine

3-Pyridinecarboxaldehyde

Ethyl 3 Fluorobenzoate

WHO cautions against to ‘vaccine nationalism’

expresspharmaAugust 20, 2020

Tag: WHO , Vaccine , coronavirus

Favorites

Countries putting their own interests ahead of others in trying to ensure supplies of a possible coronavirus vaccine are making the pandemic worse, said World Health Organization chief Tedros Adhanom Ghebreyesus.

“(Acting) strategically and globally is actually in each country’s national interest – no one is safe until everyone is safe,” he told a virtual briefing calling for an end to “vaccine nationalism”.

He said he had sent a letter to all WHO members asking them to join the multilateral COVAX vaccine effort.

Previous:A Comparison of Top Ten Best-Selling Oncology Drugs in China and the U.S. in 2019

Next:Emergency authorisation for COVID-19 vaccine possible if government decides: ICMR

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

BioPharmaSpec, the leading global Contract Research Organization (CRO) for Discovery and Preclinical Characterization of Biopharmaceuticals, has officially announced three new European facilities.

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

WHO cautions against to ‘vaccine nationalism’ | Pharmasources.com

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

PharmaSourcesNovember 15, 2024

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

You may like
More>>

Influenza Vaccine in Vial/Syringe

Group ACYW135 Meningococcal Polysaccharide Vaccine

Wholesale Price Magnesium Glycine Sofegel

Chinese Organic Pure Peppermint Oil Wholesale Bulk Price

Poliomyelitis Vaccine Type I Type III in Dragee Candy (Human Diploid Cell), Live

Wholesale price CAS 7085-85-0 ETHYL 2-CYAACRYLATE

hualan bio Group ACYW135 Meningococcal Polysaccharide Vaccine according to WHO recommended standard

Wholesale high quality and reasonable price natural wintergreen essential oil

Poliomyelitis (Live) Vaccine Type I Type III (Human Diploid Cell), Oral

Wholesale Hot Selling pear powder

WHO cautions against to ‘vaccine nationalism’

Related News

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

You may likeMore>>

You may like
More>>